Tune Therapeutics
Company

Tune Therapeutics

Biotechnology United States 80 employees
Employees
80
Contacts
3
Emails
3
Phones
1

Tune Therapeutics Overview

Headquarters
United States
Website
www.tunetx.com
Industry
Biotechnology
Employees
80
Founded
2020
Funding
175.0M

About Tune Therapeutics

The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.

Tune Therapeutics Contact Details

People in AeroLeads
4
With contact data
3
Email contacts
3
75.0% coverage
Phone contacts
1
25.0% coverage

Tune Therapeutics Org Chart

Sample employees and titles
Name Title Contact
Georgeta Puscalau Senior Vice President Quality
Email Phone
Christina Trojel-Hansen Phd CEO Cns2.bio - Entrepreneur, Biotech
View
Alicia Collins Supply Chain - Operations
Email
Brian Cosgrove Principal Scientist at Tune Therapeutics
Email

Employees by Management Level

Executive 2 profiles
Senior / Lead 1 profile
Individual contributor 1 profile

Compare Similar Companies to Tune Therapeutics